key: cord-0686831-k7kc6gfm
authors: Babady, N. Esther; McMillen, Tracy; Jani, Krupa; Viale, Agnes; Robilotti, Elizabeth V.; Aslam, Anoshe; Diver, Maureen; Sokoli, Desiree; Mason, Greg; Shah, Monika K.; Korenstein, Deborah; Kamboj, Mini
title: Performance of SARS-CoV-2 Real-time RT-PCR Tests on Oral Rinses and Saliva Samples
date: 2020-11-17
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2020.10.018
sha: e1e09d27da3a3e81925e2f2da7988a1a921c0586
doc_id: 686831
cord_uid: k7kc6gfm

Access to rapid and accurate detection of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA is essential for controlling the current global pandemic of Coronavirus Disease 2019 (COVID-19). In this study, the use of oral rinses and posterior oropharyngeal saliva as an alternative to swab collection methods from symptomatic and asymptomatic healthcare workers for the detection of SARS-CoV-2 RNA by RT-PCR was evaluated. For saliva samples, the overall agreement with oropharyngeal swabs (OPS) was 93% (Ƙ=0.84) with a sensitivity of 96.7% (95%CI:83.3-99.8%). The agreement between saliva and nasopharyngeal swabs was 97.7% (Ƙ=0.93) with a sensitivity of 94.1% (95% CI:73.0-99.7%). Oral rinses were compared with NPS only, with an overall agreement of 85.7% (Ƙ=0.65), and a sensitivity of 63% (95% CI:46.6-77.8%). The agreement between a laboratory-developed test based on the CDC RT-PCR and two commercial assays, the Xpert Xpress SARS-CoV-2 and the Cobas SARS-CoV-2 was also evaluated. The overall agreement was higher than 90%. Finally, SARS-CoV-2 RNA in saliva samples was shown to be stable, with no changes in viral loads over 24 hours at both room temperature and 4ºC. While the dilution of SARS-CoV-2 in oral rinses precluded its acceptability as a sample type, posterior oropharyngeal saliva was an acceptable alternative sample type for SARS-CoV-2 RNA detection.

Rapid and accurate viral detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical in controlling outbreaks community and healthcare settings. The current "test, track and trace" public health approach to surveillance relies heavily on testing to identify both symptomatic and asymptomatic patients. Nasopharyngeal (NPS) and oropharyngeal swabs (OPS) are two of the most common upper respiratory tract specimen types recommended for SARS-CoV-2 diagnostic testing, with NPS traditionally being the preferred sample type. However, the current pandemic has placed a significant supply strain on the availability and allocation of NPS and OPS. Additionally, collection of swabs by healthcare workers (HCW) poses a transmission risk and requires use of personal protective equipment (PPE). The limited inventory of protective gear and testing supplies have prompted evaluation of alternate sample types that can be obtained with minimized HCW exposure and which do not require specialized collection materials including swabs and viral transport media. A few recent studies and case reports have evaluated oral rinses 1, 2 and saliva samples in patients [3] [4] [5] [6] . The goal of this study was to determine the reliability of self-collected oral rinses and posterior oropharyngeal saliva as an alternative sample types for the detection of SARS-CoV-2 RNA in HCW on three different molecular platforms.

This study was conducted at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City between April 4 th , 2020 and May 11 th , 2020 at the peak of the regional epidemic (https://www1.nyc.gov/site/doh/covid/covid-19-data.page Accessed 5/19/2020). The cohort included MSKCC employees who completed an internally designed REDcap screening tool designed to determine the need for COVID-19 testing based either on symptoms or exposures. Employees with a positive symptom screen (fever or chills, cough, shortness of breath, body aches, or new loss of sense of smell or taste) or exposure to a case of COVID-19 were scheduled for testing at a location for sample collection.

For the purpose of this study, each enrolled employee had paired samples collected, either paired J o u r n a l P r e -p r o o f nasopharyngeal swab (NPS) and oral rinse (OR), paired NPS and posterior oropharyngeal saliva (saliva) or paired oropharyngeal swab (OPS) and saliva samples. Verbal consent was obtained for collection of the alternative samples. The study was granted a HIPAA waiver by the MSKCC Institutional Review B (Protocol 18-491).

NPS and OPS samples were collected using flocked swabs (Copan Diagnostics, Murrieta, CA) and placed in viral transport media (VTM). For saliva specimens, HCWs were first asked to swallow and then bring up saliva from the back of the throat and spit at least 3.0 mL of saliva into an empty sterile container. For oral rinses, HCW were asked to place 10 mL of sterile water in their mouth and with mouth closed, swish for 15 seconds, without gargling and spit the water in a sterile container. NPS and OPS were collected by dedicated nurses at test sites who were trained in the swab technique while saliva and mouth washes samples were self-collected. All samples were stored at room temperature until transport to the laboratory within 2 hours.

SARS-CoV-2 RNA was detected using a laboratory-developed real-time RT-PCR based on the CDC protocol, targeting two regions of the nucleocapsid gene (N1 and N2), with the following modifications:

Nucleic acids extraction (110 µL) was performed either on the NUCLISENS EasyMag (bioMérieux, Durham, NC) or the Chemagic 360 (PerkinElmer, Shelton, CT) following an off-board, vortexed and prelysis step inside a biosafety cabinet 2 (BSC2) hood. For mucoid mouth washings or saliva samples, comparison. Each dilution was tested in 6 replicates.

The stability of SARS-CoV-2 RNA in saliva between collection time and testing in the laboratory was evaluated. Three time points and two temperatures were evaluated to mimic the expected transport test, 600 µL of specimen was transferred to a secondary tube that was loaded on the Cobas 6800 instrument. Results were available approximately after 3 hours and automatically interpreted by the instrument software as positive if the ORF-1 gene a/b and/or E gene was detected and presumptive positive if only the E gene was detected. Mucoid samples were treated as described for the LDT test.

Results were analyzed to determine the sensitivity and specificity of the detection of SARS-CoV-2 RNA in oral rinses or saliva compared to throat or nasopharyngeal swabs as the reference method. Percent agreement between the LDT test and the two commercial SARS-CoV-2 EUA tests was calculated. Data analysis was performed in GraphPad Prism 8.4.2. (GraphPad Software Inc., La Jolla, CA).

Overall, 570 samples were collected from 285 unique HCW participants including 98 paired oral rinses and NPS, 100 paired saliva and OPS, and 87 paired saliva and NPS. 224 HCW were symptomatic, 35 were asymptomatic, and 26 had unknown symptom status at the time of sample collection. There was no difference in detection rate across samples types between symptomatic and asymptomatic participants (data not shown). (Table 1) . SARS-CoV-2 RNA was detected in 12 additional NPS only and in 2 oral rinses only. Using NPS as the reference standard, the sensitivity and specificity of SARS-CoV-2 RNA detection in oral rinses were 63.6 % (95% CI: 46.6-77.8%) and 96.9% (95% CI: 89.5-99.5%), respectively. (Figure 2A) . Finally, the mean and median Ct values in the nasopharyngeal swabs were 28.1 (95% CI: 24.5-31.8) and 29.4 (IQR 21.9-34.6) respectively while the mean and median Ct values in the corresponding saliva samples were 29.6 (95% CI: 26.0-33.2) and 32.7 (IQR 25.4-34.23) ( Figure 3A) . When looking at each individual pair, the sample type with the lower Ct value (higher viral load) varied between each paired sample, with Ct values being generally lower for NPS when compared to OR (90.4%) but with only 53.8% and 41.4% of samples having lower Ct values in NPS and OPS respectively when compared to saliva (Figures 1B and 3B) . The differences between the Ct values were statistically significant for NPS vs OR (p<0.0001) and for OPS vs saliva (p<0.05) but not for NPS vs saliva (p=0.17).

Each dilution was tested in 6 replicates and the detection rate in both sample types was determined. The LOD was determined to be 500 copies/mL in both sample types (Supplemental Table S1 ).

Three time points and two storage conditions were used to evaluate the stability of SARS-CoV-2 in saliva samples between collection and receipt in the laboratory for testing. For samples stored both in a cooler with ice packs or at room temperature, there were no significant differences in Ct values between times 0 and at 8 and 24 hours (Supplemental Table S2 ). Similar results were obtained with NPS samples. 

This study provides data to support the use of saliva for the detection of SARS-CoV-2 RNA based on evaluation of samples from healthcare workers at risk for COVID-19. SARS-CoV-2 RNA detection from saliva was superior to oropharyngeal swabs and equivalent to nasopharyngeal swabs. Furthermore, these results were validated on two commercial SARS CoV-2 PCR platforms with 91-100 % agreement. On the other hand, oral rinses were suboptimal for the diagnosis of SARS COV-2 when compared to nasopharyngeal swabs.

The performance characteristics of COVID-19 PCR on saliva and other less invasive sample types including throat gargle (oral rinses or mouthwashes) has only recently been evaluated 1, 2 . Validation of these self-collection sample types hold immense promise in enabling broad testing strategies that mitigate risk and PPE resource utilization. For saliva samples, sensitivity for detection of SARS-CoV-2 RNA compared to NPS and/or OPS ranges from 84-97% [3] [4] [5] [6] [7] [8] [9] . In one study from Hong Kong, saliva from 12 hospitalized patients with confirmed COVID-19 was tested and 11/12 (91.7%) had COVID-19 RNA detected in the initial sample 3 . However, no comparison to a paired NPS or sputum sample was made in the study. A study from Melbourne, compared paired saliva and NPS samples collected from 522 ambulatory patients 5 . SARS-CoV-2 RNA was detected in 39 NPS samples and 33/39 paired saliva samples were also positive for a sensitivity of 84.6% (95% CI 70.0%-93.1%). A sensitivity for saliva of 84.2% (95% CI 60.4%-96.6%) was also reported in a study from Bangkok when the reference method was a combination of NPS and OPS 9 . The lower sensitivity in these two studies, in contrast to the current findings on saliva and the dual reports by To et al 3, 4 is probably explained by the dilution factor; samples in the current study were tested neat compared to a 1:1 dilution with Amies media for their study. The J o u r n a l P r e -p r o o f yield for these diluted samples was similar to those of the OR samples in the current study suggesting that dilution of saliva samples could significantly impact detection rate. Notably, all of the studies mentioned above also report isolated cases where SARS-CoV-2 was only detected in saliva and missed in the corresponding NPS/OPS samples. This rare finding may be related to swab collection technique.

Comparison of data from published studies on saliva using different EUA RT-PCR platforms is challenging due to the differences in sample collection and study design. However, validation across various platforms is essential before SARS CoV-2 testing on saliva is broadly adopted . A comparison in a subset of samples in this study found high concordance among all three molecular tests suggesting that testing saliva is feasible on these commercial assays. Two recent studies evaluated saliva samples on the Xpert SARS-CoV-2 7, 8 test with a sensitivity of 96% compared to NPS sample for undiluted saliva 8 and 84% in the study where saliva samples were diluted 7 .

An interesting comparison that is often made in study with paired samples is comparing viral loads through comparison of Ct values. In the current study, overall median Ct in saliva and OPS samples was comparable but higher than NPS. Some variability in this observation was seen with higher salivary viral load which is possibly related to the phase of illness at the time of samples were collected. The symptom onset date was not systematically recorded and further analysis on yield from saliva vs other samples from time of symptom onset could not be performed.

One of the main concerns related to saliva collection has been the stability of RNA in saliva samples, which has been extensively researched over the years 10 . Samples were collected in 50-mL conical tubes that are readily available and inexpensive and SARS-CoV-2 RNA viral load remained stable for up to 24 hours at room temperature or refrigerated, well within expected time to receipt in the laboratory (less than 24 hours) at MSK. It is possible that unlike host RNA that is readily accessible to salivary RNases, SARS-CoV-2 RNA is less susceptible to degradation.

The current study has several limitations. First, while almost 300 HCWs were enrolled, the declining incidence of COVID-19 cases over the study period limited the number of positive samples enrolled in the study. Second, limited self-reported clinical information was collected at the time of testing, date of J o u r n a l P r e -p r o o f 11 symptom onset and type of symptoms were not recorded consistently throughout the study period. Given limited reagent availability, not all samples where tested using the Xpert and Cobas assays. It's possible that these two platforms may have detected additional positive samples but only a limited subset of positive saliva samples were tested limiting conclusions beyond additional proof of concept for these commercial platforms.

In summary, this report presents the most extensive data set on SARS-CoV-2 RNA detection in oral rinses to date and do not find it to be a suitable alternative to swab methods. Additionally, undiluted saliva was shown to be a better sample than oral rinses for self-collection based on comparative performance of saliva and OR with NPS and OPS. These results collectively suggest that saliva is an acceptable alternative to NPS for SARS-CoV-2 RNA detection by RT-PCR with the distinct advantages of being broadly deployable and obviating pervasive testing supply shortages. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Pharynx gargle samples are suitable for SARS-CoV-2 diagnostic use and save personal protective equipment and swabs

Gargle lavage as a safe and sensitive alternative to swab samples to diagnose COVID-19: a case report in Japan

Consistent detection of 2019 novel coronavirus in saliva

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Saliva as a non-invasive specimen for detection of SARS-CoV-2

Saliva is more senstivie for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2

Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study

An optimised saliva collection method to produce high-yield, high-quality RNA for translational research